Takeda Pharmaceutical Company Limited

Tohru Yamashita

Hideki Hirose

Asato Kina

Takeshi Yamasaki

Shizuo Kasai

Shinji Nakamura

Tsuneo Yasuma

Tomoaki Hasui

Satoshi Mikami

Zenichi Ikeda

Ryo Mizojiri

Takuya Fujimoto

Makoto Kamata

Ikuo Fujimori

Yoichi Nishikawa

Xin Liu

Masami Yamada

Hidekazu Tokuhara

Kazuaki Takami

Nobuyuki Takakura

Masaki Ogino

Masataka Murakami

Atsuko Ochida

Shinji Morimoto

Tomoya Yukawa

Nobuyuki Matsunaga

Kazuko Yonemori

Sachie Morimoto

Kyoko Toyofuku

Norio Oyabu

Takashi Nakahata

Michiko Amano

The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

Heterocyclic compounds

Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function

A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: 

Tetrahydronaphthyridine somatostatin receptor 5 antagonists

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification. 

Spiro azetidine isoxazole derivatives and their use as SSTR antagonists

A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein, or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent for the prophylaxis or treatment of diabetes mellitus are provided.

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Bicyclic compound

A compound having an SSTR5 antagonist action and use of the compound as a medicament are provided. Specifically, a compound represented by the following formula: wherein each symbol is as defined herein,or a salt thereof, a medicament comprising the compound or a salt thereof, and use of the compound or a salt thereof as an agent the prophylaxis or treatment of diabetes mellitus are provided.

Heterocyclic compound

The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes and the like, and having superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.

The present invention provides a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Growing community of inventors

Kanagawa, Japan

Tohru Yamashita